Nationwide Case Review
Call 24/7 1-800-883-9858

  • Drugs Recalls
  • Devices and Implants
  • FDA Alerts
  • About Us
  • Español
  • Contact Us
Nationwide Case Review
Call 24/7 1-800-883-9858

  • Drugs Recalls
  • Devices and Implants
  • FDA Alerts
  • About Us
  • Español
  • Contact Us
Nationwide Case Review
Call 24/7 1-800-883-9858

  • Drugs Recalls
  • Devices and Implants
  • FDA Alerts
  • About Us
  • Español
  • Contact Us

New USP Standards for Heparin Products

  • Home
  • FDA Reports FDA Alerts
  • New USP Standards for Heparin Products
Published by on October 1, 2009
Categories
  • FDA Alerts
Tags

New USP Standards for Heparin Products Will Result in Decreased Potency
Adjustments may be Needed to Achieve Desired Anticoagulant Effect in Some Patients
New Heparin to Ship Starting October 8

The U.S. Food and Drug Administration today alerted health care professionals to a change in heparin manufacturing that is expected to decrease the potency of the common anti-clotting drug.

To ensure the quality of heparin and to guard against potential contamination, the United States Pharmacopeia (USP), a nonprofit standards-setting organization, adopted new manufacturing controls for heparin. These changes include a modification of the reference standard for the drug’s unit dose.

Manufacturers in the United States label the amount of heparin included in their products based on USP standards. The changes adopted by the USP for the heparin unit dose match the World Health Organization’s International Standard (IS) unit dose definition that has been in use in Europe for many years. The revised USP reference standard and unit definition for heparin is about 10 percent less potent than the former USP unit.

A unit is the measure of a drug’s activity in the body. For heparin, a unit dose is the measure of the drug’s ability to block the blood’s natural clotting ability (anticoagulation). Heparin’s potency is determined by the dose of the drug required to produce a specific level of anticoagulation.

Manufacturers for the U.S. market have begun to make heparin using the new USP standard. While the USP manufacturing controls take effect Oct. 1 for production, the FDA has asked that they not ship this new product to customers until Oct. 8, 2009, or later. The delay will give health care providers and facilities time to learn about the changes and to make adjustments to their pharmacy procedures and dosing practices, according to John Jenkins, M.D. director of the Office of New Drugs in the FDA’s Center for Drug Evaluation and Research.

“Although the FDA-approved labeling for heparin has not changed, including the recommended doses, it is essential that health care professionals be aware of the potential difference in potency between the old and new vials of heparin when administering the drug,” said Jenkins.

Four companies market heparin in the United States. APP, the largest manufacturer, markets heparin in vials; Hospira markets heparin in intravenous bags, vials, and syringes; Baxter markets heparin in intravenous bags, and B. Braun markets heparin in intravenous bags. The FDA has asked that all manufacturers identify their new products to help pharmacies and health care professionals differentiate it from the former product.

Prescription and over–the–counter medicines available in the United States must generally meet USP’s public standards, when such standards exist. The revised standards for heparin are contained in a new USP monograph.

The monograph was revised, in part, in response to a 2007- 2008 incident of heparin contamination involving a manufacturing step in China. The contaminated heparin was associated with deaths and other adverse events in the United States. The monograph was changed to include a test for the contaminant.

Share

Review My Case

Free & Confidential Consultation

    board-certified-lawyer

    Attorney David P. Willis is a nationally recognized Trial Lawyer with more than 37 years of fighting for his clients' rights. Mr. Willis is a former Briefing Attorney for the Supreme Court of Texas and he is Board Certified in Personal Injury Trial Law since 1988.

    attorney-david-willis

    "Through his many years of dedication and service to his clients, David Willis has been successful in forcing many billion dollar corporations to make major safety changes to their products and the ways they conduct business."

    Willis-Law-Firm-awards
    Willis-Law-Firm-awards

    willis logo white

    Principle Office Location
    5005 Riverway Drive
    Suite 160
    Houston, TX 77056
    Call 24/7 1-800-883-9858

    THIS IS ATTORNEY ADVERTISING

    Contact Us Español About Us Notices & Disclaimer Privacy Policy

    © 2006-2020 Willis Law Firm. All Rights Reserved. Sitemap